AGPS and neoplasm: On the contrary, it appears that the presence of ADAs may have improved its activity, resulting in an increase in median survival time (defined as the time from tumour implantation to the time the tumour reached a volume of 1500 mm3) from 25 to 29.5 days compared with the AvFcΔXF‐treated group without preexisting ADAs.